Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
J.MukherjeeJ.RobertsS
Molecular Identity Developer Eli Lilly Mechanism Triple GLP-1, GIP, and glucagon receptor agonist FDA Status Under regulatory review (Phase 3 complete) Administration Weekly subcutaneous Triple-Agonist Mechanism Retatrutide combines all pathways: GLP-1: Core incretin signaling (shared with both Mazdutide and Tirzepatide) GIP: Second incretin pathway (shared with Tirzepatide, absent in Mazdutide) Glucagon: Hepatic energy expenditure (shared with Mazdutide, absent in Tirzepatide) For research examining the contributions of all three pathways, Retatrutide provides comprehensive coverage
Springer Nature
In the Pioneer 1 study, participants took daily oral semaglutide at doses of 3 mg, 7 mg, or 14 mg, or a placebo
Which GLP-1 is best for weight loss
US$ 27.24
US$ 20.18
US$ 24.09
US$ 24.07
US$ 25.52
